A Phase 1/Phase 2 Trial to Evaluate Safety, Immunogenicity and PSA Response of VTP-850 Prostate Cancer Immunotherapeutic in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer
Latest Information Update: 02 Aug 2024
At a glance
- Drugs VTP-850 (Primary) ; VTP-850 (Primary) ; Checkpoint kinase inhibitors
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Barinthus Biotherapeutics
- 31 Jul 2024 Planned number of patients changed from 137 to 144.
- 12 Jun 2023 According to a Vaccitech media release, the first phase of the trial is enrolling participants in the US, with plans to open further sites in Italy and Spain.
- 12 Jun 2023 According to a Vaccitech media release, a first patient has been dosed in this trial.